Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Dec 21, 2016 7:00am EST

Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea

Dec 16, 2016 7:00am EST

New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy in Treatment of NASH

Nov 25, 2016 7:00am EST

Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update

Nov 16, 2016 7:00am EST

American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102

Nov 09, 2016 7:00am EST

Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug

Nov 07, 2016 7:00am EST

Can-Fite to Participate in BIO-Europe Partnering Conference on November 7-9, 2016 in Cologne, Germany

Nov 01, 2016 7:00am EDT

Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA

Oct 25, 2016 7:15am EDT

Can-Fite Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea

Oct 13, 2016 7:00am EDT

Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH

Sep 20, 2016 7:00am EDT

Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal

  • arrow_back
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 45
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2025 Can-Fite All Rights Reserved

BrandWiz - Branding